OpGen OpGen Q1 Revenues Rise 34 Percent on Combination With Curetis OpGen said it is awaiting a clearance decision for its Unyvero pneumonia cartridge in China, where it is currently under review and pending approval. OpGen Fourth Quarter Revenues Increase 64 Percent The company's full-year revenues were $4.2 million, up 20 percent from the year-ago quarter. OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators. OpGen Enters $25M Direct Offering Agreement A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock. OpGen Preliminary Q4 Revenue Climbs 63 Percent Despite the Q4 revenue increase, sales for FY2020 dropped 13 percent year over year to $5.2 million. Nov 24, 2020 OpGen Inks $10M Private Placement Agreement Nov 11, 2020 OpGen Posts 70 Percent Increase in Q3 Revenues Amid Shuffling of Portfolio Oct 15, 2020 OpGen Posts 54 Percent Increase in Preliminary Q3 Revenues, Consolidates Product Portfolio Oct 14, 2020 OpGen Provides Additional Info to FDA on Antimicrobial Resistance Gene Panel Sep 30, 2020 Curetis Receives €350K German Government Grant to Develop Carbapenem Resistance Test Aug 20, 2020 OpGen Nabs CE-IVD Mark for SARS-CoV-2 Kit Aug 12, 2020 OpGen Q2 Revenues Climb 20 Percent Jul 15, 2020 OpGen Preliminary Q2 Revenues Increase 20 Percent Jul 13, 2020 OpGen to Distribute Menarini Silicon Cellsearch Platform in North America for COVID-19 Applications Jul 9, 2020 Curetis Gains Access to Additional €5 Million Debt Financing for COVID-19 R&D Jun 3, 2020 OpGen Expands Partnership With New York State Department of Health to Detect AMR Infections May 7, 2020 OpGen Q1 Revenues Drop 38 Percent Apr 21, 2020 Curetis, Karolinska Institute Collaborate to Identify Bacterial Co-Infections in COVID-19 Patients Apr 14, 2020 OpGen Q1 Preliminary Revenues Down 38 Percent Mar 24, 2020 OpGen Fourth Quarter Revenues Increase 8 Percent Feb 20, 2020 Curetis Preliminary 2019 Revenues Up 64 Percent Feb 12, 2020 OpGen Preliminary 2019 Revenues up 19 Percent Jan 30, 2020 Ares Genetics Collaborates With BGI on Coronavirus Testing in Europe Dec 20, 2019 FDA Clears Curetis Lower Respiratory Tract Infections Panel Nov 25, 2019 Curetis Reports 17 Percent Revenue Increase for First Nine Months of 2019 Load More Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.